Is Hepion Pharmaceuticals, Inc. (HEPA) a Buy, Sell, or Hold?
OTC : HEPA
Hepion Pharmaceuticals, Inc.
$0.053 USD
$0 (0.0%)
- Volume
- 1.76K
- Average Volume
- 22.12K
- Market Capitalization
- $617.12K
- P/E Ratio
- -0.21
- Dividend Yield
- 0.00%
- Price Target
- $70.00
- Year High
- $0.11
- Year Low
- $0.03
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.68
Company Overview
OTC
Gary S. Stetz
Biotechnology
Healthcare
HEPA
2
US
USD
Liquidity Metrics
0.00
3.68
3.68
3.54
0.00
Sales & Valuation
-$
0.00
0.33
-0.39
-0.14
Profitability
-$0.88
-$8.28M
0.00%
0.00%
-102.45%
-110.25%
P/E Metrics
-0.21
0.00
0.00
Analyst Price Target & Rating
$70.00
$70.00
$70.00
2/5
3 Analysts
-99.92%
Financial Health Scores
-130.03
1/9
$1.97M
$2.71M
$848.75K
-$2.98M
Key Metrics (TTM)
-$2.08M
0.00
0.70
3.68
-102.45%
-186.89%
-570.41%
-300.69%
0 days
Company Executives
| Name | Title |
|---|---|
| Sharen Pyatetskaya | Director of Investor Relations |
| Gary S. Stetz | Interim Chief Executive Officer & Director |
| Vincent LoPriore | Executive Chairman |
Poll Results
No votes yet today — be the first to share your view!
About Hepion Pharmaceuticals, Inc. (OTC:HEPA) Stock
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The co ... mpany, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Frequently Asked Questions
-
What is the current Hepion Pharmaceuticals, Inc. (HEPA) stock price?
-
Hepion Pharmaceuticals, Inc.(OTC:HEPA) stock price is $0.053 in the last trading session. During the trading session, HEPA stock reached the peak price of $0.11 while $0.033 was the lowest point it dropped to. The percentage change in HEPA stock occurred in the recent session was 0.0% while the dollar amount for the price change in HEPA stock was $0.
-
HEPA's industry and sector of operation?
-
The OTC listed HEPA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of HEPA?
-
Sharen Pyatetskaya | Director of Investor Relations
Gary S. Stetz | Interim Chief Executive Officer & Director
Vincent LoPriore | Executive Chairman
|
| -
How many employees does HEPA have?
-
Number of HEPA employees currently stands at 2. HEPA operates from 55 Madison Avenue, Morristown, NJ 08837, US.
-
Link for HEPA official website?
-
Official Website of HEPA is: https://www.hepionpharma.com
-
How do I contact HEPA?
-
HEPA could be contacted at phone #732 902 4000 and can also be accessed through its website. HEPA operates from 55 Madison Avenue, Morristown, NJ 08837, US.
-
How many shares of HEPA are traded daily?
-
The average number of HEPA shares traded daily for last 3 months was 22.12K.
-
What is the market cap of HEPA currently?
-
The market value of HEPA currently stands at $617.12K with its latest stock price at $0.053